Filtered By:
Cancer: Endometrial Cancer

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 190 results found since Jan 2013.

Corrigendum BMI ‑1 promotes invasion and metastasis in endometrial adenocarcinoma and is a poor prognostic factor
Oncol Rep. 2022 Aug;48(2):141. doi: 10.3892/or.2022.8352. Epub 2022 Jun 22.ABSTRACTFollowing the publication of the above paper, an interested reader drew to the authors' attention that, in Fig. 5 on p. 1637, the data panel selected to represent the 'Ishikawa/+BMI‑1 siRNA/Invasion' experiment in Fig. 5A appeared to overlap with the data shown for the 'JEC/+BMI‑1 siRNA/Migration' panel in Fig. 5C, such that they were potentially derived from the same original source. The authors have re‑examined their original data, and realize that the data panel selected for the 'Ishikawa/+BMI‑1 siRNA/Invasion' experiment in Fig. ...
Source: Oncology Reports - June 22, 2022 Category: Cancer & Oncology Authors: Jing Yu Ling Chen Zhenhua Bao Ying Liu Guohong Liu Fengling Li Lianqin Li Source Type: research

LncRNA SNHG8 participates in the development of endometrial carcinoma through regulating c-MET expression by miR-152.
CONCLUSIONS: SNHG8 is highly expressed in endometrial carcinoma, and SNHG8 targets c-MET through miR-152 to regulate the proliferation of endometrial cancer cells. PMID: 29630089 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - April 10, 2018 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

LncRNA NEAT1 regulates cervical carcinoma proliferation and invasion by targeting AKT/PI3K.
CONCLUSIONS: LncRNA NEAT1 siRNA transfection can inhibit the proliferation of cervical cancer by regulating the AKT/PI3K signaling pathway, promote cell apoptosis, and restrain cell invasion. Therefore, the lncRNA NEAT1 may be used as a molecular potential for the diagnosis and treatment of cervical cancer through regulating AKT/PI3K signaling pathway, which would be confirmed in the following study. PMID: 30024596 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - July 20, 2018 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research

Combination simvastatin and metformin synergistically inhibits endometrial cancer cell growth.
CONCLUSIONS: MET+SIM treatment synergistically inhibits endometrial cancer cell viability. This may be mediated by apoptosis and mTOR pathway inhibition. Our results provide preclinical evidence that the combination of these well-tolerated drugs may warrant further clinical investigation for endometrial cancer treatment. PMID: 31178149 [PubMed - as supplied by publisher]
Source: Gynecologic Oncology - June 5, 2019 Category: Cancer & Oncology Authors: Kim JS, Turbov J, Rosales R, Thaete LG, Rodriguez GC Tags: Gynecol Oncol Source Type: research

Clinical and biological significance of EZH2 expression in endometrial cancer.
The objective of this study was to examine the clinical significance of EZH2 expression and the therapeutic efficacy of its silencing in endometrial cancer. EZH2 expression in clinical samples was evaluated using a tissue microarray and correlated with clinical outcomes. The biological roles of EZH2 were assayed in vitro and in vivo. Gene expression was examined to reveal the molecular mechanism underlying the roles of EZH2 in endometrial cancer. We found that EZH2 overexpression was significantly correlated with disease-free and overall survival of patients with endometrial cancer. EZH2 silencing resulted in decreased cel...
Source: Cancer Biology and Therapy - October 21, 2019 Category: Cancer & Oncology Authors: Roh JW, Choi JE, Han HD, Hu W, Matsuo K, Nishimura M, Lee JS, Kwon SY, Cho CH, Kim J, Coleman RL, Lopez-Bernstein G, Sood AK Tags: Cancer Biol Ther Source Type: research

Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer.
CONCLUSIONS: By taking this integrative approach to target discovery we have streamlined the translation of high-resolution genomic data into pre-clinical in vitro studies, resulting in the identification of a number of genes that may be specifically targeted for the treatment of ovarian tumors. PMID: 23362323 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - January 29, 2013 Category: Cancer & Oncology Authors: Davis SJ, Sheppard KE, Pearson RB, Campbell IG, Gorringe KL, Simpson K Tags: Clin Cancer Res Source Type: research

A functional proteogenomic analysis of endometrioid and clear cell carcinomas using reverse phase protein array and mutation analysis: protein expression is histotype-specific and loss of ARID1A/BAF250a is associated with AKT phosphorylation
Background: Ovarian cancer is now recognized as a number of distinct diseases primarily defined by histological subtype. Both clear cell ovarian carcinomas (CCC) and ovarian endometrioid carcinomas (EC) may arise from endometriosis and frequently harbor mutations in the ARID1A tumor suppressor gene. We studied the influence of histological subtype on protein expression with reverse phase protein array (RPPA) and assessed proteomic changes associated with ARID1A mutation/BAF250a expression in EC and CCC. Methods: Immunohistochemistry (IHC) for BAF250a expression was performed on 127 chemotherapy-naive ovarian carcinomas (33...
Source: BMC Cancer - February 22, 2014 Category: Cancer & Oncology Authors: Kimberly WiegandBryan HennessySamuel LeungYemin WangZhenlin JuMollianne McGahrenSteve KallogerSarah FinlaysonKatherine Stemke-HaleYiling LuFan ZhangMichael AnglesioBlake GilksGordon MillsDavid HuntsmanMark Carey Source Type: research

Anti-tumor activity of olaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, in cultured endometrial carcinoma cells
Conclusions: Our results suggest that olaparib, a PARP inhibitor, is effective on certain endometrial cancer cell lines. Inactivation of PTEN might not affect the DNA repair function. Predictive biomarkers are warranted to utilize olaparib in endometrial cancer.
Source: Epidemiologic Perspectives and Innovations - March 13, 2014 Category: Epidemiology Authors: Aki MiyasakaKatsutoshi OdaYuji IkedaOsamu Wada-HiraikeTomoko KashiyamaAtsushi EnomotoNoriko HosoyaTakahiro KosoTomohiko FukudaKanako InabaKenbun SoneYuriko UeharaReiko KurikawaKazunori NagasakaYoko MatsumotoTakahide ArimotoShunsuke NakagawaHiroyuki Kuramo Source Type: research

908P * NUCLEAR EXPRESSION OF BCL10 HAS A ROLE IN THE REGULATION OF CELL GROWTH OF OVARIAN CANCER THROUGH THE ACTIVATION OF NF-{kappa}B-DEPENDENT CYCLIN D1 SIGNALING
Conclusions: Our findings indicate that nuclear BCL10 plays an important role in controlling the growth and progression of ovarian cancer cells through NF-B dependent cyclin D1 regulation.Disclosure: All authors have declared no conflicts of interest.
Source: Annals of Oncology - September 24, 2014 Category: Cancer & Oncology Authors: Kuo, S., Chou, C., Chen, R., Cheng, A. Tags: gynaecological cancers Source Type: research

Abstract 5203: Long non-coding RNA H19 as a novel therapeutic target for pancreatic cancer
Long non-coding RNAs (lncRNAs), non-protein coding transcripts longer than 200 nucleotides, have been recently reported to play important roles in carcinogenesis and cancer metastasis through epigenetic regulation. In the present study, we examined the expression levels and roles of lncRNA in pancreatic cancer to elucidate whether lncRNA could be a novel candidate for pancreatic cancer therapy. First, we injected PANC-1 and PK-45H, pancreatic ductal adenocarcinoma cells into the spleens of NOD/Shi-scid, IL-2Rγnull (NOG) mice, and then established novel cell lines from liver and lung metastatic nodules. Microarray analysis...
Source: Cancer Research - September 30, 2014 Category: Cancer & Oncology Authors: Yoshimura, H., Matsuda, Y., Suzuki, T., Naito, Z., Ishiwata, T. Tags: Molecular and Cellular Biology Source Type: research

BAF57 expression of ovarian cancer cells and drug sensitivity
This article is protected by copyright. All rights reserved.
Source: Cancer Science - January 22, 2015 Category: Cancer & Oncology Authors: Takahiro Yamaguchi, Tomoko Kurita, Kazuto Nishio, Junichi Tsukada, Toru Hachisuga, Yasuo Morimoto, Yoshiko Iwai, Hiroto Izumi Tags: Original Article Source Type: research

Aurora kinase A has a significant role as a therapeutic target and clinical biomarker in endometrial cancer.
Abstract Aurora kinase A (AURKA) regulates the cell cycle checkpoint and maintains genomic integrity. AURKA is overexpressed in various malignant tumors and its upregulation induces chromosomal instability, which leads to aneuploidy and cell transformation. To investigate the role of AURKA in endometrial cancer, we evaluated the association of immunohistochemical expression of AURKA with clinicopathological factors. Furthermore, we examined the effects of AURKA inhibition by transfected siRNA in HEC‑1B cells on colony‑forming ability, invasion and migration capacity, and chemosensitivity. Immunohistochemical ...
Source: International Journal of Oncology - January 22, 2015 Category: Cancer & Oncology Authors: Umene K, Yanokura M, Banno K, Irie H, Adachi M, Iida M, Nakamura K, Nogami Y, Masuda K, Kobayashi Y, Tominaga E, Aoki D Tags: Int J Oncol Source Type: research

Expression of BAF57 in ovarian cancer cells and drug sensitivity
In this study, we investigated BAF57 expression in ovarian cancer cell lines and their sensitivities to cisplatin, doxorubicin, paclitaxel, and 5‐fluorouracil. BAF57 expression was strongly correlated with sensitivities to cisplatin, doxorubicin, and 5‐fluorouracil in 10 ovarian cancer cell lines. Paclitaxel sensitivity was also correlated with BAF57 expression, but without significance. In A2780 ovarian cancer cells, knockdown of BAF57 using specific siRNA increased cell cycle arrest at G1 phase and the sensitivities to these anticancer agents. cDNA microarray analysis of A2780 cells transfected with BAF57 siRNA showe...
Source: Cancer Science - February 25, 2015 Category: Cancer & Oncology Authors: Takahiro Yamaguchi, Tomoko Kurita, Kazuto Nishio, Junichi Tsukada, Toru Hachisuga, Yasuo Morimoto, Yoshiko Iwai, Hiroto Izumi Tags: Original Article Source Type: research